Cutaneous presentation of posttransplant lymphoproliferative disorder

Journal of the American Academy of Dermatology

Volumn 42, Issue 5 II, 2000, Pages 923-926

  Schumann, Keith W ^a   Oriba, Howard A ^a   Bergfeld, Wilma F ^a   Hsi, Eric D ^a   Hollandsworth, Kimberly ^a  

^a USC UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; AUTOPSY; CASE REPORT; CLINICAL FEATURE; ERYTHEMA; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUNG TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; PATHOGENESIS; PRIORITY JOURNAL; SKIN MANIFESTATION;

EID: 0034069703     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0190-9622(00)90273-1     Document Type: Article

References (28)

1. Starzl TE. In discussion of: Murray JE, Wilson RE, Tilney NL, et al. Five years' experience in renal transplantation with immunosuppressive drugs: survival, function, complications and the role of lymphocyte depletion by thoracic duct fistula. Ann Surg 1968;168:416.
2. Riddler SA, Breinig MC, McKnight LC. Increased levels of circulating Epstein-Bart virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lyphoproliferative disease in solid-organ transplant recipients. Blood 1994;84:972-84.
3. Rea D, Fourcade C, Leblond V, et al. Patterns of Epstein-Barr virus and replicative gene expression in Epstein-Barr virus B cell lymphoproliferative disorders after organ transplantation. Transplantation 1994;58:317-24.
4. Berg LC, Copenhaver CM, Gruber SA, et al. B-cell lymphoproliferative disorders in solid-organ transplant patients: detection of Epstein-Barr virus by in situ hybridization. Human Pathology 1992;23:159-63.
5. Armitage JM, Kormos RL, Stuart RS, et al. Posttransplant lymphoprolerative disease in thoracic organ transplant patients: ten years of cyclosporine-based Immunosuppression. J Heart Lung Transplant 1991;10:877-87.
6. Fisher A, Blanche S, LeBidiios J, et al. Anti-B cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation. N Engl J Med 1991;324:1451-6.
7. Makowka L, Nalesnik MA, Steiber A, et al. Control of post-transplant lymphoproliferative disorders and Kaposi's sarcoma by modulation of immunosuppression. In:Good RA, editor. Nature, cellular and biochemical bases, and management of immunodeficiency. Stuttgart-New York: KF Schattauer Verlag; 1987.
8. Nalesnik MA, Jaffee R, Starzl TE, et al. The pathology of post-transplant lymphoproliferative disorders reoccurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol 1989;133:173-92.
9. Knowles DM, Cesarman E, Chadburn, et al. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplant lymphoproliferative disorders. Blood 1995;85:552-65.
10. Craig FE, Gulley ML, Banks PM. Posttransplantation lymphoproliferative disorders. Am J Clin Pathol 1992;99:265-76.
11. Hanto DW, Frizzera G, Purfilo DT, et al. Clinical spectrum of lymphoproliferative disorders in renal transplant recipients and evidence for the role of Epstein-Barr virus. Cancer Res 1981;41:4253-61.
12. Morrison VA, Dunn DL, Manivel C. Clinical characteristics of post-transplant lymphoproliferative disorders. Am J Med 1994; 97:14-24.
13. Nalesnik MA. Posttransplant lymphoproliferative disorders (PTLD): current perspectives. Semin Thorac Cardiovasc Surg 1996;8:139-48.
14. Gonthier DM, Hartman G, Hooley JL. Posttransplant lymphoproliferative disorder presenting as an isolated skin lesion. Am J Kidney Dis 1992;19:600-3.
15. Preiksaitis JK. Lymphoproliferative disorders in renal transplant recipients: virologic aspects. Clin Transplant 1992;6:235-9.
16. Young L, Alfieri C, Hennessy K, et al. Expression of Epstein-Barr virus transformation-associated genes in tissue of patients with EBV lymphoproliferative disease. N Eng J Med 1989:321;1080-5.
17. Cleary ML, Nalesnik MA, Shearer WT, Sklar J. Clonal analysis of transplant-associated lymphoproliferations based on the structure of the genomic termini of the Epstein-Barr virus. Blood 1988;72:349-52.
18. Chadburn A, Cesarman E, Knowles D. Molecular pathology of posttransplantation lymphoproliferative disorders. Semin Diagn Pathol 1997;14:15-26.
19. Frizzera G, Hanto DW, Kazimiera J, et al. Polymorphic diffuse B cell hyperplasia and lymphoma in renal transplant recipients. Cancer Res 1981;41:4262-79.
20. Starzl TE, Nalesnik MA, Makowa L. The diagnosis and treatment of posttransplant lymphoproliferative disorders. Curr Probl Surg 1988;25:365-472.
21. Ferry JA, Jacobson JO, Conti D, et al. Lymphoproliferative disorders and hematologic malignancies following organ transplantation. Mod Pathol 1989;2:583-92.
22. Swinnen L J, Nordin MR, Fisher SG, et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Eng J Med 1990;323:1723-8.
23. Penn I. Cancers following cyclosporine therapy. Transplantation 1987;43:32-5.
24. Swinnen LJ. Treatment of organ transplant-related lymphoma. Hematol Oncol Clin North Am 1997;11:963-73.
25. Hanto DW, Frizzera G, Gajl-Peczalska KJ, et al. Epstein-Barr virus-induced B-cell lymphoma after renal transplantation: acyclovir therapy and transition from polyclonal to monoclonal B-cell proliferation. N Eng J Meal 182;306:913-8.
26. O'Brien S, Bernert RA, Logan JL, Lien YH. Remission of post-transplant lymphoproliferative disorder after interferon alfa therapy. J Am Soc Nephrol 1997;8:1483-90.
27. Leblond V, Sullon L, Dorent R, Davi F, Bilker M-O, Gabarre J, et al. Lymphoproliferative disorders after organ transplantation: a report of 24 cases observed in a single center. J Clin Oncol 1995;13:961-8.
28. Naslesnik, M. Clinicopathologic features of posttransplant lymphoproliferative disorders. Ann Transplant 1997;2:33-7.